Rho-associated kinase (ROCK) function is essential for cell cycle progression, senescence and tumorigenesis

  1. Sandra Kümper  Is a corresponding author
  2. Faraz K Mardakheh
  3. Afshan McCarthy
  4. Maggie Yeo
  5. Gordon W Stamp
  6. Angela Paul
  7. Jonathan Worboys
  8. Amine Sadok
  9. Claus Jørgensen
  10. Sabrina Guichard
  11. Christopher J Marshall
  1. Institute of Cancer Research, United Kingdom
  2. Cancer Research UK London Research Institute, United Kingdom
  3. Cancer Research UK Manchester Institute, United Kingdom

Abstract

Rho-associated kinases 1 and 2 (ROCK1/2) are Rho-GTPase effectors that control key aspects of the actin cytoskeleton, but their role in proliferation and cancer initiation or progression is not known. Here we provide evidence that ROCK1 and ROCK2 act redundantly to maintain actomyosin contractility and cell proliferation and that their loss leads to cell-cycle arrest and cellular senescence. This phenotype arises from down-regulation of the essential cell-cycle proteins CyclinA, CKS1 and CDK1. Accordingly, while loss of either Rock1 or Rock2 had no negative impact on tumorigenesis in mouse models of non-small cell lung cancer and melanoma, loss of both blocked tumor formation, as no tumors arise in which both Rock1 and Rock2 have been genetically deleted. Our results reveal an indispensable role for ROCK, yet redundant role for isoforms 1 and 2, in cell cycle progression and tumorigenesis, possibly through the maintenance of cellular contractility.

Article and author information

Author details

  1. Sandra Kümper

    Division of Cancer Biology, Institute of Cancer Research, London, United Kingdom
    For correspondence
    sandra.kuemper@icr.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
  2. Faraz K Mardakheh

    Division of Cancer Biology, Institute of Cancer Research, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  3. Afshan McCarthy

    Division of Cancer Biology, Institute of Cancer Research, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  4. Maggie Yeo

    Division of Cancer Biology, Institute of Cancer Research, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  5. Gordon W Stamp

    Experimental Pathology Laboratory, Cancer Research UK London Research Institute, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  6. Angela Paul

    Division of Cancer Biology, Institute of Cancer Research, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  7. Jonathan Worboys

    Cancer Research UK Manchester Institute, Manchester, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  8. Amine Sadok

    Division of Cancer Biology, Institute of Cancer Research, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  9. Claus Jørgensen

    Cancer Research UK Manchester Institute, Manchester, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  10. Sabrina Guichard

    Division of Cancer Biology, Institute of Cancer Research, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  11. Christopher J Marshall

    Division of Cancer Biology, Institute of Cancer Research, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.

Ethics

Animal experimentation: All animal procedures were approved by the Animal Ethics Committee of the Institute of Cancer Research in accordance with National Home Office regulations under the Animals (Scientific Procedures) Act 1986. The date of approval of the current project license under which this work was carried out was the 07/09/13.

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 7,941
    views
  • 1,706
    downloads
  • 124
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Sandra Kümper
  2. Faraz K Mardakheh
  3. Afshan McCarthy
  4. Maggie Yeo
  5. Gordon W Stamp
  6. Angela Paul
  7. Jonathan Worboys
  8. Amine Sadok
  9. Claus Jørgensen
  10. Sabrina Guichard
  11. Christopher J Marshall
(2016)
Rho-associated kinase (ROCK) function is essential for cell cycle progression, senescence and tumorigenesis
eLife 5:e12203.
https://doi.org/10.7554/eLife.12203

Share this article

https://doi.org/10.7554/eLife.12203

Further reading

    1. Cancer Biology
    2. Cell Biology
    Francesca Butera, Julia E Sero ... Chris Bakal
    Research Article Updated

    The canonical NF-κB transcription factor RELA is a master regulator of immune and stress responses and is upregulated in pancreatic ductal adenocardinoma (PDAC) tumours. In this study, we characterised previously unexplored endogenous RELA-GFP dynamics in PDAC cell lines through live single-cell imaging. Our observations revealed that TNFα stimulation induces rapid, sustained, and non-oscillatory nuclear translocation of RELA. Through Bayesian analysis of single-cell datasets with variation in nuclear RELA, we predicted that RELA heterogeneity in PDAC cell lines is dependent on F-actin dynamics. RNA-seq analysis identified distinct clusters of RELA-regulated gene expression in PDAC cells, including TNFα-induced RELA upregulation of the actin regulators NUAK2 and ARHGAP31. Further, siRNA-mediated depletion of ARHGAP31 and NUAK2 altered TNFα-stimulated nuclear RELA dynamics in PDAC cells, establishing a novel negative feedback loop that regulates RELA activation by TNFα. Additionally, we characterised the NF-κB pathway in PDAC cells, identifying how NF-κB/IκB proteins genetically and physically interact with RELA in the absence or presence of TNFα. Taken together, we provide computational and experimental support for interdependence between the F-actin network and the NF-κB pathway with RELA translocation dynamics in PDAC.

    1. Cancer Biology
    Thi Mong Quynh Pham, Thanh Nhan Nguyen ... Le Son Tran
    Research Article

    In the realm of cancer immunotherapy, the meticulous selection of neoantigens plays a fundamental role in enhancing personalized treatments. Traditionally, this selection process has heavily relied on predicting the binding of peptides to human leukocyte antigens (pHLA). Nevertheless, this approach often overlooks the dynamic interaction between tumor cells and the immune system. In response to this limitation, we have developed an innovative prediction algorithm rooted in machine learning, integrating T cell receptor β chain (TCRβ) profiling data from colorectal cancer (CRC) patients for a more precise neoantigen prioritization. TCRβ sequencing was conducted to profile the TCR repertoire of tumor-infiltrating lymphocytes (TILs) from 28 CRC patients. The data unveiled both intra-tumor and inter-patient heterogeneity in the TCRβ repertoires of CRC patients, likely resulting from the stochastic utilization of V and J segments in response to neoantigens. Our novel combined model integrates pHLA binding information with pHLA-TCR binding to prioritize neoantigens, resulting in heightened specificity and sensitivity compared to models using individual features alone. The efficacy of our proposed model was corroborated through ELISpot assays on long peptides, performed on four CRC patients. These assays demonstrated that neoantigen candidates prioritized by our combined model outperformed predictions made by the established tool NetMHCpan. This comprehensive assessment underscores the significance of integrating pHLA binding with pHLA-TCR binding analysis for more effective immunotherapeutic strategies.